Key clinical point: Guselkumab showed sustained safety and effectiveness for treatment of psoriatic arthritis in biologic-naive patients at 1 year.

Major finding: At 52 weeks, 71% and 75% of patients in two guselkumab treatment groups showed an improvement of at least 20% in ACR measures, compared with baseline.

Study details: The data come from 739 adults with active psoriatic arthritis who were part of the DISCOVER-2 study and randomized to guselkumab or placebo.

Disclosures: The study was supported by Janssen. Many authors reported financial relationships with Janssen and other pharmaceutical companies. Nine of the 15 authors are employees of Janssen (a subsidiary of Johnson & Johnson) and own Johnson & Johnson stock or stock options.